Abstract | INTRODUCTION: AREAS COVERED: Research to elucidate the pathophysiology of Guillain-Barré syndrome has led to the development of drugs directed towards new potential therapeutic targets. This review offers a comprehensive view of the current treatment based upon the physiopathology. EXPERT OPINION: Patients with Guillain-Barré syndrome need a multidisciplinary approach, limitation to walk unaided and disability score are indicators for treatment as well as the presence of autonomic dysfunction and pain. Admission to intensive care units should be considered for those patients presenting with respiratory failure, bulbar involvement and progression of the disease. Research aimed to deciphering the pathophysiology of the disease, discovering new biomarkers and establishing algorithms of prediction of both the disease and its outcomes is warranted.
|
Authors | Paula Restrepo-Jiménez, Yhojan Rodríguez, Paulina González, Christopher Chang, M Eric Gershwin, Juan-Manuel Anaya |
Journal | Expert opinion on biological therapy
(Expert Opin Biol Ther)
Vol. 18
Issue 6
Pg. 619-631
(06 2018)
ISSN: 1744-7682 [Electronic] England |
PMID | 29681203
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Immunoglobulins, Intravenous
- Immunologic Factors
|
Topics |
- Disease Progression
- Guillain-Barre Syndrome
(immunology, therapy)
- Humans
- Immunoglobulins, Intravenous
(therapeutic use)
- Immunologic Factors
(therapeutic use)
- Immunotherapy
(adverse effects, methods)
- Plasma Exchange
(methods)
- Plasmapheresis
(methods)
|